The company spotlighted its flagship automated immunoassay platform, AFIAS, featuring advanced diagnostic assays such as IGRA-TB for latent tuberculosis detection, PENKID for early prediction of acute kidney injury, TDM for therapeutic drug monitoring, HOMA-IR for assessing insulin resistance, and vitamin D deficiency testing. These assays are designed to deliver rapid, accurate results, addressing critical needs in clinical diagnostics.

Boditech Med also introduced its veterinary diagnostics lineup, including AFIAS-VET, an automated immunoassay system, and VETCHROMA 3, a manual alternative for point-of-care testing. The company additionally showcased UROCHROMA, a urine analysis platform, and VETCHEMIS, a whole-blood biochemistry analyzer—reinforcing its commitment to comprehensive diagnostic solutions across both human and animal health sectors.
Boditech Med aims to leverage its presence at ADLM 2025 to reinvigorate growth in North and South American markets. Following a surge in demand during the COVID-19 pandemic and a subsequent stabilization phase, the company has identified 2025 as a critical year for strategic expansion. Plans include bolstering regional sales operations and broadening its distributor network.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr